Pharmaceutical

Gilead Sciences Aids in Reducing Cancer Care Disparities: Dale Shares Her Breast Cancer Journey and the Power of Information Sharing

NORTHAMPTON, MA / ACCESSWIRE / March 7, 2024 / Gilead SciencesFor many people living with cancer, hearing about the experiences…

10 months ago

Curium Announces First Commercial Doses in Italy of PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer

PARIS, March 07, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that the first commercial…

10 months ago

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

BOSTON and ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical…

10 months ago

TOMI Expands SteraMist iHP Corporate Service Contracts and Clients

Company announces new partners including The University of Texas and Rising Pharmaceuticals FREDERICK, Md., March 07, 2024 (GLOBE NEWSWIRE) --…

10 months ago

Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference

Together with its partner, Frontage Laboratories, Telomir’s poster focused on pre-clinical data demonstrating Telomir-1’s ability to elongate telomere caps on…

10 months ago

Scorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023

Estimates Sequential Reduction in the Fourth Quarter of 2023 Operating Loss by Over $3.3 Million or Approximately 30% Compared to the…

10 months ago

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Launched VOQUEZNA® (vonoprazan) tablets in November 2023 for the treatment of Erosive GERD (gastroesophageal reflux disease), achieving net revenues of…

10 months ago

Ventyx Biosciences Announces $100 Million Private Placement of Common Stock

SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on…

10 months ago

Bright Green Corporation (BGXX) submits for historic DEA Registration for Production of Schedule I and Schedule II controlled substances.

The application follows the Company’s approval from the New Mexico Board of Pharmacy this year. GRANTS, NM, March 07, 2024…

10 months ago